LANDIOLOL, AN ULTRASHORT-ACTING β1-ADRENOCEPTOR ANTAGONIST, HAS PROTECTIVE EFFECTS IN AN LPS-INDUCED SYSTEMIC INFLAMMATION MODEL
- 1 May 2009
- journal article
- basic science-aspects
- Published by Ovid Technologies (Wolters Kluwer Health) in Shock
- Vol. 31 (5), 515-520
- https://doi.org/10.1097/shk.0b013e3181863689
Abstract
Previous studies suggest that the blockade of β-adrenoceptors augments the release of inflammatory regulators in response to proinflammatory stimuli. High-mobility group box 1 (HMGB-1) is a key mediator in the development of sepsis. We investigated whether landiolol, a short-acting selective β1-adrenoceptor-blocking agent, can attenuate acute lung injury and cardiac dysfunction in a rat model of endotoxin-induced sepsis. We administered LPS i.v. to rats, with or without simultaneous treatment with landiolol (0.1 mg/kg per min). After the induction of sepsis by LPS treatment, we measured cytokine and HMGB-1 levels in the serum and lung tissue. In addition, we performed histopathology, determined wet-to-dry weight ratios, and measured cardiac function and cell signaling in the lung. Cotreatment with landiolol was associated with significantly less severe disease, as assessed by lung histopathology and cardiac function metrics. Serum and lung HMGB-1 levels were lower over time among landiolol-treated animals. Furthermore, nuclear factor-κB activity was inhibited by the administration of landiolol. Cotreatment with the selective β1-adrenoceptor-blocking agent landiolol protects against acute lung injury and cardiac dysfunction in a rat model of LPS-induced systemic inflammation. Treatment was associated with a significant reduction in serum levels of the inflammation mediator HMGB-1 and histological lung damage.Keywords
This publication has 41 references indexed in Scilit:
- Mechanisms of sepsis-induced cardiac dysfunctionCritical Care Medicine, 2007
- Recognizing and Managing Severe Sepsis: A Common and Deadly ThreatSouthern Medical Journal, 2007
- The Lung in Sepsis: Guilty or Innocent?Endocrine, Metabolic & Immune Disorders - Drug Targets, 2006
- The vagal nerve as a link between the nervous and immune system in the instance of polymicrobial sepsisLangenbecks Archives Of Surgery, 2006
- Sepsis-induced myocardial dysfunction and myocardial protection from ischemia/reperfusion injuryFrontiers in Bioscience-Landmark, 2006
- MAPK-dependent regulation of IL-1- and β-adrenoreceptor-induced inflammatory cytokine production from mast cells: Implications for the stress responseBMC Immunology, 2004
- The Epidemiology of Sepsis in the United States from 1979 through 2000New England Journal of Medicine, 2003
- Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort studyIntensive Care Medicine, 2001
- Time Course of a New Ultrashort-Acting β-Adrenoceptor-Blocking Drug, ONO-1101: Comparison with Those of Esmolol and Propranolol by Using the Canine Isolated, Blood-Perfused Heart PreparationsJournal of Cardiovascular Pharmacology, 1998
- Development of a Highly Cardioselective Ultra Short-Acting .BETA.-Blocker, ONO-1101.CHEMICAL & PHARMACEUTICAL BULLETIN, 1992